Literature DB >> 35379254

Clinical and molecular analysis of four unrelated Chinese families with pathogenic KLHL40 variants causing nemaline myopathy 8.

Haiming Yuan1,2, Qingming Wang1,2, Xiumei Zeng1, Peiqing He1,2, Wanfang Xu1, Hongmei Guo1, Yanhui Liu3,4, Yangyang Lin5.   

Abstract

BACKGROUND: Homozygous or compound heterozygous variants in the KLHL40 gene cause nemaline myopathy 8 (NEM8), a severe autosomal recessive muscle disorder characterized by prenatal polyhydramnios, fetal akinesia or hypokinesia, joint contractures, fractures, respiratory failure and dysphagia. Currently, 46 individuals with NEM8 have been described in the literature, and 30 variants in KLHL40 have been identified.
RESULTS: Here, we reported five individuals from four unrelated Chinese families who presented common features of nemaline myopathy and infrequent clinical characteristics. Whole-exome sequencing (WES) was used to identify the causative gene. WES identified a recurrent missense variant c.1516A>C (p.Thr506Pro) and a novel frameshift variant c.543del (p.Ser182Profs*17) in KLHL40 in patient 1, a nonsense variant c.602G>A (p.Trp201*) and a missense variant c.1516A>C (p.Thr506Pro) in KLHL40 in patient 2, and homozygous variant c.1516A>C (p.Thr506Pro) in KLHL40 in patient 3 and both siblings (patients 4 and 5), all of which were confirmed by Sanger sequencing. Next, we estimated the incidence of this disorder in the southern and northern Chinese population to be 4.59/106 and 2.95/106, respectively, based on the cumulative allele frequency of pathogenic variants in internal database.
CONCLUSION: The results of our study expand the mutation spectrum of KLHL40 and enrich our understanding of the clinical characteristics of NEM8. Genetic counseling was provided for the four families involved in this study. Given the severity and the relatively high incidence of this condition, we strongly suggest that KLHL40 be incorporated into a carrier screening panel for the Chinese population.
© 2022. The Author(s).

Entities:  

Keywords:  Carrier screening; Fetal akinesia; KLHL40; Nemaline myopathy; Polyhydramnios; Respiratory failure

Mesh:

Substances:

Year:  2022        PMID: 35379254      PMCID: PMC8981653          DOI: 10.1186/s13023-022-02306-9

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


Introduction

Nemaline myopathy (NEM) is a heterogeneous group of congenital myopathies with broad clinical phenotypes that range from mild muscle dysfunction to severe neonatal muscle weakness, often leading to fetal or early death. Currently, at least twelve genes have been recognized as causing nemaline myopathy. Some exhibit an autosomal recessive pattern, such as CFL2, KLHL40, KLHL41, LMOD3, MYPN, NEB, TNNT1. Less often, they exhibit an autosomal dominant pattern, including KBTBD13, TNNT3 and TPM2, or an autosomal dominant/recessive pattern, such as ACTA1, TPM3 [1]. Nemaline myopathy 8 (MIM #615348), caused by biallelic pathogenic variants in KLHL40, is one of the most severe forms of NEM. It is characterized by early-onset severe generalized muscle weakness or hypokinesia, multiple joint contractures, fractures, respiratory failure and dysphagia apparent at birth. The average age of death is 5 months [2]. NEM8 is considered to be a very rare autosomal recessive muscle disorder, with only 46 NEM8 individuals being reported worldwide; 30 variants in KLHL40 have been identified to date [2-9]. Recently, two genetic testing centers from southern China analyzed the frequency of pathogenic variants of KLHL40 in their in-house database and proposed that the condition was not-so-rare in southern Chinese individuals, suggesting that the gene/variants should be included in a carrier screening panel and considered in prenatal diagnosis when congenital myopathies are suspected [8, 9]. However, this evidence is from only two centers and is limited. Our genetic testing center, also located in southern China, identified an additional five individuals with NEM8 from four unrelated Chinese families. The patients presented common features of NEM8, and the clinical features were delineated in detail. The results of our study expand the genetic variant spectrum of KLHL40 and enrich our understanding of the clinical characteristics of this disorder, which will be beneficial for improving the prenatal diagnosis of NEM8. Furthermore, we provide further evidence that NEM8 has been historically underdiagnosed and that KLHL40 should be listed in the carrier screening panel.

Materials and methods

Ethical compliance

This study was approved by the Ethics Committee of Dongguan Maternal and Child Health Care Hospital. Written informed consent was obtained from the legal guardians for the publication of any potentially identifiable images or data included in this article.

Trio-based whole exome sequencing (WES)

Trio-based whole-exome sequencing was performed for families to screen for causal variants. Sequencing was performed with an Illumina NovaSeq 6000 (Illumina, San Diego, CA, USA). Suspected variants were verified by Sanger sequencing. The pathogenicity of the sequence variants was interpreted according to the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) guidelines [10].

Results

Patient 1

A 30-year-old woman (gravida 2, para 1) felt reduced fetal movement compared with her previous pregnancy. The prenatal ultrasound scan showed obvious bilateral knee joint contractures, talipes equinovarus and inflexion and increased thickness of planta skin (6.8 mm) at 31 weeks (Fig. 1A). Karyotype and chromosomal microarray of amniocytes were normal. MLPA detected no deletion of exons 7 and 8 in SMN1. The women underwent vaginal delivery at 37 weeks. A female baby weighing 2250 g was born cyanotic and with dyspnea. The baby had generalized hypotonia, lack of spontaneous limb movements, bilateral elbow, hip and knee flexion contractures and mild skin edema. The baby passed away at 16 days of age due to severe respiratory failure and pneumonia.
Fig. 1

Ultrasound images. A Ultrasound images showing bilateral knee joint contractures (a), talipes equinovarus and inflexion (b), and increased thickness of planta skin (6.8 mm) (c) in patient 1. B Ultrasound images showing closed hands, flexed wrists (a), bilateral talipes equinovarus (b), extended legs and knee joint contractures (c), and thickening of the forehead soft tissue (7.9 mm) (d) in patient 3

Ultrasound images. A Ultrasound images showing bilateral knee joint contractures (a), talipes equinovarus and inflexion (b), and increased thickness of planta skin (6.8 mm) (c) in patient 1. B Ultrasound images showing closed hands, flexed wrists (a), bilateral talipes equinovarus (b), extended legs and knee joint contractures (c), and thickening of the forehead soft tissue (7.9 mm) (d) in patient 3 Trio-based WES identified compound heterozygous variants, c.543del (p.Ser182Profs*17) and c.1516A>C (p.Thr506Pro) in KLHL40 in the patient (Fig. 2a). Both asymptomatic parents were heterozygous carriers. The paternally inherited frameshift variant is novel, and it leads to a premature termination codon in the BACK domain that consequently results in loss-of-function of KLHL40. The maternally inherited missense variant has been proven to be a founder mutation in ethnic Chinese individuals [8]. Both variants can be classified as pathogenic according to the ACMG/AMP guidelines [10].
Fig. 2

Variant identification by Sanger sequencing. Compound heterozygous variants c.543del and c.1516A>C in KLHL40 were detected in patient 1 (a); compound heterozygous variants c.602G>A and c.1516A>C in KLHL40 were detected in patient 2 (b); and homozygous variant c.1516A>C in KLHL40 was detected in patient 3 (c) and both siblings (patients 4 and 5) (d). The red arrow indicates the variant site

Variant identification by Sanger sequencing. Compound heterozygous variants c.543del and c.1516A>C in KLHL40 were detected in patient 1 (a); compound heterozygous variants c.602G>A and c.1516A>C in KLHL40 were detected in patient 2 (b); and homozygous variant c.1516A>C in KLHL40 was detected in patient 3 (c) and both siblings (patients 4 and 5) (d). The red arrow indicates the variant site

Patient 2

A 28-year-old nulliparous woman presented with reduced fetal movement and progressive polyhydramnios. Amniocentesis showed a normal karyotype and chromosomal microarray. She underwent cesarean section at 35 weeks due to membrane rupture, and 2600 ml of liquid was noted during delivery. A male baby weighing 2150 g was born apneic and hypotonic. Multiple abnormalities were noted, including distinctive facial features (prominent forehead, hypertelorism, low-set ears and broad nasal bridge), severe hypotonia, multiple joint contractures, spontaneous limb fractures, bilateral clubfeet, talipes valgus, absent palmar and plantar crease, wide space between fingers and toes and cryptorchidism. The baby suffered from severe pneumonia and passed away at 20 days of age. Trio-based WES identified compound heterozygous variants, c.602G>A (p.Trp201Ter) and c.1516A>C (p.Thr506Pro) in KLHL40 in the patient, which were inherited from the father and mother, respectively (Fig. 2b). The paternally inherited nonsense variant was predicted to truncate the BACK domain of KLHL40. Both variants can be categorized as pathogenic according to the ACMG/AMP guidelines [10].

Patient 3

A 27-year-old woman in her first pregnancy underwent an anomaly scan at 17 weeks of gestation, and the fetus was incidentally found to have bilateral talipes equinovarus. Persistent ultrasonic scans confirmed the condition at 21, 23 and 25 weeks of gestation. Then, the woman felt progressively reduced fetal movement. Amniocentesis showed a normal karyotype and chromosomal microarray. The ultrasonic scan at 29 weeks of gestation showed a fetus with abnormal posture, including persistently closed hands, flexed wrists, extended legs and knee joint contractures in addition to bilateral talipes equinovarus. In addition, there was increased thickness in the soft tissue of the forehead (7.9 mm), suggesting fetal edema (Fig. 1B). The pregnancy was terminated at 30 weeks of gestation. Trio-based WES revealed a homozygous variant, c.1516A>C (p.Thr506Pro) in KLHL40, in a DNA sample from the aborted fetus. Both parents were asymptomatic heterozygous carriers (Fig. 2c).

Patients 4 and 5

A 27-year-old nulliparous woman in her first pregnancy felt persistently reduced fetal movement. The prenatal scan at 26 weeks incidentally detected polyhydramnios. Serial ultrasound showed fetal growth retardation and progressive polyhydramnios and no obvious limb movements. The women underwent vaginal delivery at 31 weeks due to preterm premature membrane rupture resulting from polyhydramnios. A female baby weighing 1500 g was born cyanotic with no respiratory effort. The baby had generalized hypotonia, dysphagia and akinesia and required ventilation support and tube feeding. She once suffered from pleural effusion and sepsis and eventually recovered from active treatment. She was given special care, including daily physical massage and extremity fixation using bone fixation devices. At five years old, no obvious joint contractures or fractures were noted. However, she was still akinetic, with facial muscle involvement. Her eyes would open during both waking and sleeping states. She was able to slightly shake her head, move her mouth and eyes and feel emotion, but she was not able to vocalize or move her trunk, extremities and facial muscles. She can cry, maintains minimal eye contact and responds to ambient events or personal interactions. Her nerve conduction velocity was normal, and electromyography implied myopathy. Karyotype and chromosomal microarray results were normal. MLPA detected no deletion of exons 7 and 8 in SMN1. However, WES was not performed for the family. The woman had another unplanned spontaneous pregnancy. Again, she experienced reduced fetal movement and progressive polyhydramnios that were strikingly similar to her previous pregnancy. The anomaly scan at 28 weeks of gestation showed a fetus with abnormal posture, including closed hands, flexed wrists, bilateral knee contractures and clubfeet. Then, the woman decided to terminate the pregnancy and undergo whole-exome sequencing. Trio-based WES revealed a homozygous variant, c.1516A>C (p.Thr506Pro) in KLHL40, in a DNA sample from the aborted fetus. Both parents were asymptomatic heterozygous carriers (Fig. 2d). Next, we analyzed the DNA sample of the female patient, which had been still retained in our laboratory, and it expectedly revealed the same KLHL40 homozygous variant.

Discussion

The KLHL40 gene consists of 6 exons and encodes the 621-amino acid KLHL40 protein, which has an N-terminal BTB/BACK domain and 5 C-terminal Kelch repeats that are predicted to form a beta-propeller structure. The KLHL40 protein has the highest expression in skeletal muscle and lower expression in heart, with little to no expression in the other tissues examined [2, 11]. KLHL40 belongs to the superfamily of kelch-repeat-containing proteins that form characteristic β-propeller structures, binding substrate proteins that are involved in a wide variety of functions, such as cell migration, morphology, and protein expression. As a stabilizer of the thin filament proteins leiomodin-3 and nebulin, KLHL40 is necessary for both myogenesis and skeletal muscle maintenance [11, 12]. Homozygous or compound heterozygous variants in KLHL40 result in NEM8, one of the most severe forms of NEM [2]. To date, only 46 individuals with NEM8 have been reported worldwide and the identified variants in KLHL40 were scattered through all exons (Fig. 3) The main clinical manifestations include prenatal polyhydramnios (51.3%), fetal akinesia/hypokinesia (77.4%), multiple joint contractures (89.7%), spontaneous fractures (60.7%), respiratory failure (97.4%) and dysphagia (96.8%) during the neonatal period, with the average age of death being 5 months. Furthermore, most patients had facial involvement and muscle weakness. Fetal edema was an infrequent phenotype (9.7%) [2-9]. As reported, multiple joint contractures and spontaneous fractures are very common in NEM8. Surprisingly, our female patient (patient 4) never experienced joint contractures or spontaneous fractures, but her sibling (patient 5) suffered from obvious multiple joint contractures at 28 weeks fetal gestation, even though they carried the same homozygous variant, c.1516A>C (p.Thr506Pro) in KLHL40. This is the first report indicating that the variant c.1516A>C in KLHL40 did not cause joint contractures or fractures, with phenotypic variability observed even within the same family. A recent report demonstrated that pyridostigmine was effective for the severe KLHL40 phenotype [13]. To date, pyridostigmine or other neuromuscular junction-acting molecules have not been tried in the female patient. The illness of the female in this report was effectively controlled, and no sign of deterioration occurred. Her current status is similar to the locked-in state reported for a male patient with the homozygous variant c.1405G>T (p.Gly469Cys) in KLHL40, as reported by Kawase et al. (2015) [3]. She is the longest-lived patient with the c.1516A>C (p.Thr506Pro) variant in KLHL40 to date. Fetal edema has been infrequently described for NEM8 [3, 5, 9], and here, we add another two cases showing a fetal edema phenotype, suggesting that fetal edema is one of the clinical features of NEM8, which needs to be explored further. Therefore, this study enriches our understanding of the clinical characteristics of NEM8.
Fig. 3

KLHL40 variants identified to date in individuals with NEM8. Schematic presentation of the genomic structure of the KLHL40 gene (upper) and its encoded protein, KLHL40, with the N-terminal BTB-BACK domain and 5 C-terminal kelch repeats (lower). The localization of variants and substitutions identified is depicted with dots. Black: variants reported in the literature; red: novel variants identified in this study; blue: the founder mutation in Chinese patients with NEM8

KLHL40 variants identified to date in individuals with NEM8. Schematic presentation of the genomic structure of the KLHL40 gene (upper) and its encoded protein, KLHL40, with the N-terminal BTB-BACK domain and 5 C-terminal kelch repeats (lower). The localization of variants and substitutions identified is depicted with dots. Black: variants reported in the literature; red: novel variants identified in this study; blue: the founder mutation in Chinese patients with NEM8 Currently, 11 individuals from 9 unrelated Chinese families harboring 4 different KLHL40 variants have been reported. All patients carried the c.1516A>C (p.Thr506Pro) variant in KLHL40, which has been suggested as a founder mutation in Chinese patients with NEM8 [5, 7–9]. Our study describes an additional five individuals from four unrelated Chinese families who all harbored the known founder mutation, with patients 3 and 4 and 5 being homozygous, further supporting that KLHL40 c.1516A>C is a Chinese-specific founder mutation causing NEM8. Furthermore, a novel frameshift variant of KLHL40, c.543del (p.Ser182Profs*17), was identified in patient 1. This variant has not been reported in the medical literature, HGMD or ClinVar and was not found in the 1000 Genomes Project or the Genome Aggregation Database. The variant is predicted to truncate the protein; therefore, it was regarded as pathogenic according to ACMG/AMP guidelines. This newly identified variant further expands the KLHL40 mutation spectrum. Although KLHL40-related nemaline myopathy has rarely been reported in the Chinese population, two genetic testing centers in southern China recently proposed that the carrier frequency of KLHL40 in the population may be underestimated and that KLHL40 should be considered for incorporation into a carrier screening panel [8, 9]. However, this evidence is from only two genetic testing centers and is therefore limited or could be considered biased. Our genetic testing center, also located in southern China, identified five individuals from four unrelated Chinese families who were both molecularly and clinically diagnosed with NEM8. Next, we assessed the allele frequency (AF) of pathogenic variants, and we reviewed all the detected variants in KLHL40 in our in-house database (n = 3035). Excluding variants of uncertain significance, another four pathogenic variants were revealed (Additional file 1: Table S1). The overall AF in our cohort was estimated to be nearly 0.0043; thus, the predicted incidence of NEM8 would be 4.59/106. Next, to evaluate the AF of KLHL40 in Northern China, we sought support from Chigene (Beijing) Translational Medical Research Center Co., Ltd., which is a leading company in precision medicine in Northern China that has their own carrier screening database (n = 58,540). We identified 201 individuals carrying pathogenic or likely pathogenic KLHL40 variants (Additional file 1: Table S2). The overall AF in the database was estimated to be close to 0.0034; thus, the predicted incidence of NEM8 would be 2.95/106 in Northern China. Even then, its incidence may still be underestimated for two main reasons. Some variants of uncertain significance could eventually be categorized as pathogenic. In addition, most NEM8 individuals die during the embryonic or neonatal period, so clinicians lack an understanding of this disorder, which could lead to a lack of molecular diagnoses in most cases. Thus, our study provides strong evidence suggesting that the AF of KLHL40 has been severely underestimated historically and that this gene should be included in a carrier screening panel for the Chinese population. Given the severity and unique clinical characteristics of NEM8, clinicians should be mindful of this condition, and prenatal diagnosis is urgently needed.

Conclusions

We reported five individuals with NEM8 from four unrelated Chinese families. The results of our study help to expand the mutation spectrum of KLHL40 and enrich the clinical knowledge of this disorder. We strongly suggest that KLHL40 be included in a carrier screening panel and as in first-tier testing of severe neonatal myopathy in ethnic Chinese patients, especially those with a significant family history of congenital myopathies. Additional file 1. Table S1. Estimated pathogenic variants in KLHL40 in our local database on ACMG guidelines. Table S2. Estimated pathogenic or likely pathogenic variants in KLHL40 in Chigene database on ACMG guidelines.
  13 in total

1.  Nemaline myopathy with KLHL40 mutation presenting as congenital totally locked-in state.

Authors:  Koya Kawase; Ichizo Nishino; Mari Sugimoto; Takao Togawa; Tokio Sugiura; Masanori Kouwaki; Tetsuya Kibe; Norihisa Koyama; Kenji Yokochi
Journal:  Brain Dev       Date:  2015-02-24       Impact factor: 1.961

2.  Founder Mutation c.1516A>C in KLHL40 Is a Frequent Cause of Nemaline Myopathy With Hyponatremia in Ethnic Chinese.

Authors:  Han-Chih Hencher Lee; Shun Wong; Frank Ying-Kit Leung; Luen-Cheung Ho; Siu-Ki Timothy Chan; Tsui-Hang Sharon Fung; Kwok-Fan Kwan; Kin-Cheong Eric Yau; Ka-Wah Li; Wai-Nang Yau; Hoi-Ki Cynthia Leung; Sammy Pak-Lam Chen; Chloe Miu Mak
Journal:  J Neuropathol Exp Neurol       Date:  2019-09-01       Impact factor: 3.685

3.  Identification of KLHL40 mutations by targeted next-generation sequencing facilitated a prenatal diagnosis in a family with three consecutive affected fetuses with fetal akinesia deformation sequence.

Authors:  Tai-Heng Chen; Xia Tian; Pao-Lin Kuo; Hui-Ping Pan; Lee-Jun C Wong; Yuh-Jyh Jong
Journal:  Prenat Diagn       Date:  2016-11-18       Impact factor: 3.050

4.  Mild clinical presentation in KLHL40-related nemaline myopathy (NEM 8).

Authors:  Andreea M Seferian; Edoardo Malfatti; Caroline Bosson; Laurent Pelletier; Jessica Taytard; Veronique Forin; Teresa Gidaro; Elena Gargaun; Pierre Carlier; Julien Fauré; Norma B Romero; John Rendu; Laurent Servais
Journal:  Neuromuscul Disord       Date:  2016-07-29       Impact factor: 4.296

5.  KLHL40 deficiency destabilizes thin filament proteins and promotes nemaline myopathy.

Authors:  Ankit Garg; Jason O'Rourke; Chengzu Long; Jonathan Doering; Gianina Ravenscroft; Svetlana Bezprozvannaya; Benjamin R Nelson; Nadine Beetz; Lin Li; She Chen; Nigel G Laing; Robert W Grange; Rhonda Bassel-Duby; Eric N Olson
Journal:  J Clin Invest       Date:  2014-06-24       Impact factor: 14.808

6.  KLHL40-related nemaline myopathy with a sustained, positive response to treatment with acetylcholinesterase inhibitors.

Authors:  D Natera-de Benito; A Nascimento; A Abicht; C Ortez; C Jou; J S Müller; T Evangelista; A Töpf; R Thompson; C Jimenez-Mallebrera; J Colomer; H Lochmüller
Journal:  J Neurol       Date:  2016-01-11       Impact factor: 4.849

7.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

Review 8.  Nemaline myopathies: a current view.

Authors:  Caroline A Sewry; Jenni M Laitila; Carina Wallgren-Pettersson
Journal:  J Muscle Res Cell Motil       Date:  2019-06-21       Impact factor: 2.698

9.  Next generation sequencing in a large cohort of patients presenting with neuromuscular disease before or at birth.

Authors:  Emily J Todd; Kyle S Yau; Royston Ong; Jennie Slee; George McGillivray; Christopher P Barnett; Goknur Haliloglu; Beril Talim; Zuhal Akcoren; Ariana Kariminejad; Anita Cairns; Nigel F Clarke; Mary-Louise Freckmann; Norma B Romero; Denise Williams; Caroline A Sewry; Alison Colley; Monique M Ryan; Cathy Kiraly-Borri; Padma Sivadorai; Richard J N Allcock; David Beeson; Susan Maxwell; Mark R Davis; Nigel G Laing; Gianina Ravenscroft
Journal:  Orphanet J Rare Dis       Date:  2015-11-17       Impact factor: 4.123

10.  A novel and recurrent KLHL40 pathogenic variants in a Chinese family of multiple affected neonates with nemaline myopathy 8.

Authors:  Sheng Yi; Yue Zhang; Zailong Qin; Shang Yi; Haiyang Zheng; Jingsi Luo; Qifei Li; Jin Wang; Qi Yang; Mengting Li; Fei Chen; Qiang Zhang; Qinle Zhang; Yiping Shen
Journal:  Mol Genet Genomic Med       Date:  2021-05-12       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.